Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
February 20 2023 - 5:00PM
Business Wire
Maternova, Inc., accelerating advances in maternal and infant
health through innovative, accessible solutions, and MedMira Inc.
(TSXV: MIR), a developer and manufacturer of rapid diagnostics,
today announced that the companies have entered into a
multinational distribution agreement. Under the agreement,
Maternova will have exclusive distribution rights across Latin
America and non-exclusive rights in the United States for MedMira’s
Reveal®, Multiplo® and Miriad® brands that are aimed at reducing
HIV, hepatitis, syphilis and other infectious and sexually
transmitted diseases.
“Sexually transmitted infections are a growing threat to
maternal and infant health. MedMira’s Rapid Vertical Flow® platform
provides tests with immediate results that are highly sensitive and
specific, all of the qualities needed by clinicians,” stated Meg
Wirth, Founder and Chief of Strategy at Maternova. “These tests
will be an invaluable resource in a broad range of healthcare
settings and a timely addition to Maternova’s targeted distribution
channels in Latin America and the United States.”
The new partnership increases Maternova’s product lines by
offering additional unique, quality products, including the
Multiplo TP/HIV rapid test that delivers 100% sensitivity in
identifying co-infections and is helping to reduce mother-to-child
transmission (MTCT) of syphilis and HIV. In addition, the Reveal G4
HIV rapid test provides the highest sensitivity and specificity as
outlined in recent studies conducted by the CDC. All products are
exclusively produced in Canada in an FDA- and MDSAP-certified
manufacturing facility and conform to all required standards.
“MedMira has developed a number of highly valuable and essential
rapid tests to provide immediate quality answers in any setting.
Our core focus is the development and manufacturing of our
technologies and products, and we are delighted to partner with
Maternova to access new markets and new customers. Maternova’s
commercialization expertise and extensive network in Latin America
and the United States offer a highly valued next step in our mutual
growth,” said Hermes Chan, CEO of MedMira.
Action on Disaster Relief 2023 Meeting
Maternova is a sponsor of the Action on Disaster Relief
(ADR2023) event being held in Panama City, Panama from February
22-23. MedMira’s products will be available to review at
Maternova’s exhibit booth 5. Maternova CEO Prakash Veenam will also
chair the Regional International Support & Coordination panel
on February 23 at 10:50 a.m. EST. He will discuss how international
organizations can pool their resources to reduce mortality rates
caused by natural disasters, including timely medical support,
humanitarian disaster relief operations, and coordinating strategic
relief activities.
About Maternova Maternova is a health solutions company
and the leading global marketplace for lifesaving, evidence-based
medical innovations in maternal, newborn and reproductive health.
Founded in 2009, Maternova launched the first-of-its-kind
e-commerce marketplace for distributors, governments and
humanitarian organizations to research, source and fulfill orders
of trusted and rigorously tested medical devices, diagnostics and
nutritional products that enhance care. Since 2015, Maternova has
impacted the lives of more than 1.2 million mothers and babies
around the world. Learn more about Maternova and its mission at
www.maternova.net.
About MedMira MedMira is a leading developer and
manufacturer of Rapid Vertical Flow Technology® diagnostics. The
Company’s tests provide hospitals, labs, clinics and individuals
with instant disease diagnosis, such as HIV, syphilis, hepatitis
and SARS-CoV-2, in just three easy steps. The Company’s tests are
sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and
Miriad® brands. Based on its patented Rapid Vertical Flow
Technology, MedMira’s rapid HIV test is the only one in the world
to achieve regulatory approvals in Canada, the United States, China
and the European Union. MedMira’s corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia,
Canada. For more information visit www.medmira.com and follow us on
Twitter and LinkedIn.
This news release contains forward-looking statements, which
involve risk and uncertainties and reflect the Company’s current
expectation regarding future events, including statements regarding
possible regulatory approval, product launch, future growth, and
new business opportunities. Actual events could materially differ
from those projected herein and depend on a number of factors
including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of
corporate alliances and other risks detailed from time to time in
the Company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230220005270/en/
Media: Maternova, Inc. Robin Fastenau
robin.fastenau@maternova.net
MedMira, Inc. Markus Meile Chief Financial Officer
ir@medmira.com
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From May 2024 to Jun 2024
Mirion Technologies (NYSE:MIR)
Historical Stock Chart
From Jun 2023 to Jun 2024